Comparative Pharmacology
Head-to-head clinical analysis: ALBAMYCIN versus E E S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBAMYCIN versus E E S.
ALBAMYCIN vs E.E.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
None Documented
None Documented
3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment.
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance.
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic